Farmacoterapia segura y eficaz en niños

1 van Riet-Nales DA, de Jager KE, Schobben AF, et al. The availability and age-appropriateness of medicines authorized for children in The Netherlands. Br J Clin Pharmacol 2011; 72:465–73.
2 Bellis JR, Kirkham JJ, Thiesen S, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med 2013; 11:238.
3 Novack GD. What does the food and drug administration safety and innovation act mean for you? Ocul Surf 2013; 11:206–9.
4 Turner MA, Catapano M, Hirschfeld S, et al. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014; 73:2–13.
5 Watts G. WHO launches campaign to make drugs safer for children. BMJ 2007; 335:1227.
6 World Health Organization. Development of paediatric medicines: points to consider in pharmaceutical development. http://www.who.int/medicines/areas/quality_safety/ quality_assurance/Rev3-PaediatricMedicinesDevelopment_QAS08-257Rev3_
17082011.pdf (accessed 1 Oct 2015).
7 European Medicines Agency QWPPC. Guideline on the pharmaceutical development of medicines for paediatric use. http://www.ema.europa.eu (accessed 1 Oct 2015).
8 van Riet-Nales DA, Schobben AF, Egberts TC, et al. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review. Clin Ther 2010; 32:924–38.
9 Ivanovska V, Rademaker CM, van Dijk L, et al. Pediatric drug formulations: a review of challenges and progress. Pediatrics 2014; 134:361–72.
10 Venables R, Batchelor H, Hodson J, et al. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Int J Pharm 2015; 480:55–62.
11 Ranmal S, Tuleu C. Demonstrating evidence of acceptability: the ‘catch-22’ of pediatric formulation development. Clin Pharmacol Ther 2013; 94:582–4.
12 European Directorate for the Quality of Medicines and Healthcare. Standard terms, 2015. https://standardterms.edqm.eu/stw/controlleterms/communications/0# (accessed 1 Oct 2015).
13 Tshefu A, Lokangaka A, Ngaima S, et al. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet 2015; 385:1758–66.
14 Strickley RG, Iwata Q, Wu S, et al. Pediatric drugs—a review of commercially available oral formulations. J Pharm Sci 2008; 97:1731–74.
15 Bauters T, Claus B, Willems E, et al. What’s in a drop? Optimizing strategies for administration of drugs in pediatrics. Int J Clin Pharm 2012; 34:679–81.
16 Walsh J, Bickmann D, Breitkreutz J, et al. Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm 2011; 415:221–31.
17 Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs 2014; 74:1871–89.
18 Winch PJ, Gilroy KE, Doumbia S, et al. Prescription and administration of a 14-day regimen of zinc treatment for childhood diarrhea in Mali. Am J Trop Med Hyg 2006; 74:880–3.
19 Ameen VZ, Pobiner BF, Giguere GC, et al. Ranitidine (Zantac) syrup versus
Ranitidine effervescent tablets (Zantac) EFFER dose) in children: a single-center taste preference study. Paediatr Drugs 2006; 8:265–70.
20 Lopez FL, Ernest TB, Tuleu C, et al. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin Drug Deliv 2015; 12:1727–40.
21 Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci 2015; 75:2–9.
22 Klingmann V, Seitz A, Meissner T, et al. Acceptability of uncoated mini-tablets in neonates-a randomized controlled trial. J Pediatr 2015; 167:893–6.e2.
23 Ceschi A, Hofer KE, Rauber-Luthy C, et al. Paracetamol orodispersible tablets: a risk for severe poisoning in children? Eur J Clin Pharmacol 2011; 67:97–9.
24 Rustemkyzy C, Belton P, Qi S. Preparation and characterisation of ultra-rapidly dissolving orodispersible films for treating and preventing iodine deficiency in the paediatric population. J Agric Food Chem 2015; 63:9831–8.
25 van Riet-Nales DA, de Neef BJ, Schobben AF, et al. Acceptability of different oral formulations in infants and preschool children. Arch Dis Child 2013; 98:725–31.
26 Sazawal S, Dhingra P, Dhingra U, et al. Compliance with home-based fortification strategies for delivery of iron and zinc: its effect on haematological and growth markers among 6–24 months old children in north India. J Health Popul Nutr 2014; 32:217–26.
27 Hirve S, Bhave S, Bavdekar A, et al. Low dose ‘Sprinkles’—an innovative approach to treat iron deficiency anemia in infants and young children. Indian Pediatr 2007; 44:91–100.
28 Klingmann V, Spomer N, Lerch C, et al. Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. J Pediatr 2013; 163:1728–32.e1.
29 Kluk A, Sznitowska M, Brandt A, et al. Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot study. Int J Pharm 2015; 485:1–6.
30 Van de Vijver E, Desager K, Mulberg AE, et al. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J Pediatr Gastroenterol Nutr 2011;53:61–4.
31 Kreeftmeijer-Vegter AR, de Meijer M, Wegman KA, et al. Development and evaluation of age-appropriate film-coated tablets of levamisole for paediatric use (2–18 years). Expert Opin Drug Deliv 2013; 10:293–300.
32 Vanprapar N, Cressey TR, Chokephaibulkit K, et al. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J 2010; 29:940–4.
33 Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2014; 58:413–22.
34 Kayitare E, Vervaet C, Mehuys E, et al. Taste-masked quinine pamoate tablets for treatment of children with uncomplicated Plasmodium falciparum malaria. Int J Pharm 2010; 392:29–34.
35 Charkoftaki G, Kytariolos J, Macheras P. Novel milk-based oral formulations: proof of concept. Int J Pharm 2010; 390:150–9.
36 Gerrard SE, Baniecki ML, Sokal DC, et al. A nipple shield delivery system for oral drug delivery to breastfeeding infants: microbicide delivery to inactivate HIV. Int J Pharm 2012; 434:224–34.
37 Bar-Shalom D. Necessity of rethinking oral pediatric formulations. Clin Ther 2014; 36:180–3.
38 Wallace LS, Keenum AJ, DeVoe JE. Evaluation of consumer medical information and oral liquid measuring devices accompanying pediatric prescriptions. Acad Pediatr 2010; 10:224–7.
39 van Riet-Nales DA, Ferreira JA, Schobben AF, et al. Methods of administering oral formulations and child acceptability. Int J Pharm 2015; 491:261–7.
40 Batchelor HK, Kendall R, Desset-Brethes S, et al. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Eur J Pharm Biopharm 2013; 85(Pt B):833–42.
41 Aleksovski A, Dreu R, Gasperlin M, et al. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert Opin Drug Deliv 2015; 12:65–84.
42 Preis M. Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use. AAPS PharmSciTech 2015; 16:234–41.
43 Walsh J, Cram A, Woertz K, et al. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients. Adv Drug Deliv Rev 2014; 73:14–33.
44 Nellis G, Metsvaht T, Varendi H, et al. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Arch Dis Child 2015; 100:694–9.
45 Salunke S, Brandys B, Giacoia G, et al. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2—the pilot version. Int J Pharm 2013; 457:310–22.
46 European Medicines Agency. Excipients labelling. 2015. http://www.ema.europa.eu/ ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000387. jsp&mid=WC0b01ac05808c01f6 (accessed 1 Oct 2015).
47 Allegaert K. Neonates need tailored drug formulations. World J Clin Pediatr 2013; 2:1–5.
48 Sam T, Ernest TB, Walsh J, et al. A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms—an application for paediatric dosage form selection. Int J Pharm 2012; 435:115–23.
49 Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: key considerations and current challenges. Adv Drug Deliv Rev 2014; 73:102–26.
50 van den Ban E, Souverein PC, Swaab H, et al. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. Atten Defic Hyperact Disord 2010; 2:213–20.
51 Richey RH, Shah UU, Peak M, et al. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr 2013; 13:81.
52 Ricci BM. Bridging studies in support of oral pediatric formulation development. Int J Pharm 2013; 457:323–6.